Healthcare Asia’s business portfolio consists of a wide array of products in different oncology areas, stemming from its strong partnerships with suppliers in Europe and United States. Healthcare Asia monitors the list of new FDA-approved drugs closely to keep up with the ever-changing environment of the pharmaceutical industry.
The extensive range includes drugs such as but not limited to:
- Iclusig (Ponatinib)
- Keytruda (Pembrolizumab)
- Lartruvo (Olaratumab)
- Lysodren (Mitotane)
- Opdivo (Nivolumab)
- Tagrisso (Osimertinib)
- Xtandi (Enzalutamide)
- Yervoy (Ipilimumab)
- Zelboraf (Vemurafenib)
- Zejula (Niraparib)